FocalTherics (NASDAQ:FOCL – Get Free Report) Director Fran Schulz acquired 10,000 shares of the stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $4.75 per share, with a total value of $47,500.00. Following the completion of the transaction, the director owned 15,100 shares of the company’s stock, valued at approximately $71,725. This represents a 196.08% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
FocalTherics Stock Performance
FOCL stock opened at $4.36 on Thursday. The stock’s 50 day moving average price is $5.37. The stock has a market capitalization of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 0.99.
FocalTherics (NASDAQ:FOCL – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The firm had revenue of $13.20 million during the quarter. Equities analysts forecast that FocalTherics will post -0.78 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on FOCL shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd. Mizuho set a $15.00 target price on FocalTherics and gave the company an “outperform” rating in a report on Friday, July 17th. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research note on Monday. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a report on Friday, August 14th. Finally, Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $7.75.
Read Our Latest Stock Report on FOCL
FocalTherics Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
Read More
- Five stocks we like better than FocalTherics
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for FocalTherics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FocalTherics and related companies with MarketBeat.com's FREE daily email newsletter.
